Sage Therapeutics (SAGE) – Analysts’ Recent Ratings Changes

Sage Therapeutics (NASDAQ: SAGE) has recently received a number of price target changes and ratings updates:

• 4/27/2024 – Sage Therapeutics was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 4/26/2024 – Sage Therapeutics had its price target lowered by analysts at Royal Bank of Canada from $26.00 to $15.00. They now have a “sector perform” rating on the stock.
• 4/26/2024 – Sage Therapeutics had its price target lowered by analysts at HC Wainwright from $28.00 to $25.00. They now have a “neutral” rating on the stock.
• 4/26/2024 – Sage Therapeutics had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $28.00 to $19.00. They now have a “neutral” rating on the stock.
• 4/26/2024 – Sage Therapeutics had its price target lowered by analysts at Mizuho from $20.00 to $18.00. They now have a “neutral” rating on the stock.
• 4/26/2024 – Sage Therapeutics had its price target lowered by analysts at Truist Financial Co. from $22.00 to $18.00. They now have a “hold” rating on the stock.
• 4/26/2024 – Sage Therapeutics had its price target lowered by analysts at Canaccord Genuity Group Inc. from $21.00 to $17.00. They now have a “hold” rating on the stock.
• 4/25/2024 – Sage Therapeutics had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
• 4/19/2024 – Sage Therapeutics was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
• 4/18/2024 – Sage Therapeutics had its price target lowered by analysts at Scotiabank from $34.00 to $19.00. They now have a “sector outperform” rating on the stock.
• 4/18/2024 – Sage Therapeutics had its price target lowered by analysts at Oppenheimer Holdings Inc. from $25.00 to $17.00. They now have a “market perform” rating on the stock.
• 4/18/2024 – Sage Therapeutics had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
• 4/18/2024 – Sage Therapeutics had its price target lowered by analysts at TD Cowen from $30.00 to $16.00. They now have a “buy” rating on the stock.
• 4/17/2024 – Sage Therapeutics was downgraded by analysts at Bank of America Co. from a “neutral” rating to an “underperform” rating. They now have a $14.00 price target on the stock, down previously from $24.00.
• 4/17/2024 – Sage Therapeutics had its “neutral” rating reaffirmed by analysts at Wedbush. They now have a $24.00 price target on the stock.
• 4/17/2024 – Sage Therapeutics had its “neutral” rating reaffirmed by analysts at HC Wainwright. They now have a $28.00 price target on the stock.
• 3/26/2024 – Sage Therapeutics had its price target raised by analysts at JPMorgan Chase & Co. from $24.00 to $29.00. They now have an “overweight” rating on the stock.

Sage Therapeutics Trading Down 1.7 %

Shares of SAGE stock traded down $0.24 during trading hours on Tuesday, hitting $13.94. The company’s stock had a trading volume of 626,247 shares, compared to its average volume of 1,027,838. The business has a fifty day moving average of $18.38 and a 200-day moving average of $20.61. Sage Therapeutics, Inc. has a twelve month low of $10.92 and a twelve month high of $59.99. The stock has a market cap of $838.91 million, a price-to-earnings ratio of -1.66 and a beta of 0.86.

Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.80) EPS for the quarter, missing analysts’ consensus estimates of ($1.63) by ($0.17). Sage Therapeutics had a negative return on equity of 56.81% and a negative net margin of 552.52%. The company had revenue of $7.90 million for the quarter, compared to analysts’ expectations of $5.26 million. During the same quarter in the prior year, the business posted ($2.46) EPS. The company’s revenue for the quarter was up 139.4% compared to the same quarter last year. On average, equities analysts expect that Sage Therapeutics, Inc. will post -6.49 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of SAGE. CWM LLC boosted its holdings in Sage Therapeutics by 274.2% in the third quarter. CWM LLC now owns 1,205 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 883 shares during the last quarter. SG Americas Securities LLC lifted its stake in shares of Sage Therapeutics by 11.0% in the 3rd quarter. SG Americas Securities LLC now owns 18,607 shares of the biopharmaceutical company’s stock valued at $383,000 after purchasing an additional 1,847 shares in the last quarter. Harbor Capital Advisors Inc. grew its holdings in shares of Sage Therapeutics by 65.2% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 34,773 shares of the biopharmaceutical company’s stock worth $716,000 after purchasing an additional 13,720 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Sage Therapeutics by 17.4% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,289 shares of the biopharmaceutical company’s stock worth $191,000 after purchasing an additional 1,375 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in Sage Therapeutics by 27.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 39,583 shares of the biopharmaceutical company’s stock valued at $815,000 after buying an additional 8,561 shares during the period. 99.22% of the stock is currently owned by hedge funds and other institutional investors.

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.